{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-025848","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2024-07-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.035845+00:00","generated_at":"2026-05-31T23:54:14.485261+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Elite Pharma FY2024 revenue $56.6M (+65% YoY); operating profit $10.8M (+192%)","bullets":["Revenue of $56.6M, up $22.4M (65%) from prior fiscal year.","Operating profit $10.8M, up $7.1M (192%) YoY.","Net income attributable to common shareholders was $20.1M.","Growth driven by commercial launch of Elite label product line in FY2024.","Conference call on July 2, 2024 at 11:30 AM EDT for business update."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-025848","json":"https://secwatch.observer/filing/0001493152-24-025848.json","markdown":"https://secwatch.observer/filing/0001493152-24-025848.md","text":"https://secwatch.observer/filing/0001493152-24-025848.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224025848/0001493152-24-025848-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315224025848/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T23:54:14.485261+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}